ORKA Oruka Therapeutics, Inc.
FY2025 10-K
Oruka Therapeutics, Inc. (ORKA) filed its fiscal year 2025 10-K annual report with the SEC on Mar 12, 2026. This page provides AI-powered analysis of the filing, including business overview, management discussion, risk factors, and key financial metrics from XBRL data.
AI Filing AnalysisFY2025 10-K
Business Overview
- • Core business: Clinical-stage biopharma developing novel monoclonal antibodies for psoriasis and inflammatory/immunology indications
- • New emphasis: Acquisition and rebranding of Pre-Merger Oruka in 2024, launching dual lead programs ORKA-001 and ORKA-002 targeting IL-23p19 and IL-17A/F
Management Discussion & Analysis
- • No revenue generated; net loss $105.4M for 2025; accumulated deficit $189.2M as of December 31, 2025
- • Operating cash flow negative $88.2M; cash, equivalents, and marketable securities $479.6M at year-end
Risk Factors
- • FDA regulatory delays risk impacting approval timeline for product candidates ORKA-001 and ORKA-002 amid ongoing Phase 1 and Phase 2 trials
- • Geopolitical tensions and elevated interest rates contributing to market volatility that may hinder timely capital raises for ongoing clinical development
Get deeper insights on Oruka Therapeutics, Inc.
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.